Recognition of bipolar disorder type i before the first manic episode: Challenges and developments

Expert Review of Neurotherapeutics

Volumn 13, Issue 7, 2013, Pages 795-807

  Noto, Mariane Nunes ^a   De Souza Noto, Cristiano ^a   De Jesus, Danilo Rocha ^b   Zugman, André ^a   Mansur, Rodrigo B ^a   Berberian, Arthur A ^a   Leclerc, Emilie ^a   McIntyre, Roger S ^c   Correll, Christoph U ^d,e   Brietzke, Elisa ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d ZUCKER HILLSIDE HOSPITAL   (United States)

^e DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Bipolar disorder; Endophenotypes; High risk; Hypomania; Mania; Neuroprogression

Indexed keywords

ANTIDEPRESSANT AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PLACEBO; PSYCHOSTIMULANT AGENT; VALPROIC ACID;

ANTERIOR CINGULATE; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BRAIN; BRAIN FUNCTION; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CYCLOTHYMIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EMOTION; ENDOPHENOTYPE; EVOKED RESPONSE; FAMILY HISTORY; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPOMANIA; LONG TERM CARE; MAJOR DEPRESSION; MANIA; MENTAL PATIENT; MONOTHERAPY; MOOD DISORDER; MOOD DISORDER QUESTIONNAIRE; NEUROBIOLOGY; NEUROCHEMISTRY; NEUROPHYSIOLOGY; PATHOPHYSIOLOGY; PERSONALITY; PREPULSE INHIBITION; PREVALENCE; PROGENY; PROGNOSIS; PSYCHOEDUCATION; PSYCHOSIS; PSYCHOTHERAPY; QUALITY OF LIFE; RECOGNITION; REM SLEEP; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SENSORY GATING; SUICIDE; SUICIDE ATTEMPT; TEMPERAMENT; THALAMUS; TREATMENT INDICATION; VERBAL MEMORY; WHITE MATTER;

BIPOLAR DISORDER; BRAIN; DISEASE PROGRESSION; ENDOPHENOTYPES; HUMANS; PRODROMAL SYMPTOMS; RISK FACTORS;

EID: 84883147752     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2013.811132     Document Type: Review

References (105)

1. Post RM, Denicoff KD, Leverich GS et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J. Clin. Psychiatry 64(6), 680-690; quiz 738 (2003).
2. Kapczinski F, Vieta E, Andreazza AC et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci. Biobehav. Rev 32(4), 675-692 (2008).
3. Berk M, Kapczinski F, Andreazza AC et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev 35(3), 804-817 (2011).
4. Osby U, Brandt L, Correia N, Ekbom A, Sparén P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch. Gen. Psychiatry 58(9), 844-850 (2001).
5. McIntyre RS, Danilewitz M, Liauw SS et al. Bipolar disorder and metabolic syndrome: an international perspective. J. Affect. Disord. 126(3), 366-387 (2010).
6. Vancampfort D, Vansteelandt K, Correll CU et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am. J. Psychiatry 170(3), 265-274 (2012).
7. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry 70(8), 1078-1090 (2009).
8. Angst J, Gamma A. A new bipolar spectrum concept: a brief review. Bipolar Disord. 4(Suppl. 1), 11-14 (2002).
9. Akiskal HS. The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV. J. Clin. Psychopharmacol. 16(2 Suppl. 1), S4-S14 (1996).
10. Kelsoe JR. Arguments for the genetic basis of the bipolar spectrum. J. Affect. Disord. 73(1-2), 183-197 (2003).
11. Berk M, Malhi GS, Hallam K et al. Early intervention in bipolar disorders: clinical, biochemical and neuroimaging imperatives. J. Affect. Disord. 114(1-3), 1-13 (2009).
12. Perugi G, Micheli C, Akiskal HS et al. Polarity of the first episode, clinical characteristics, and course of manic depressive illness: a systematic retrospective investigation of 320 bipolar I patients. Compr. Psychiatry 41(1), 13-18 (2000).
13. Baethge C, Smolka MN, Gruschka P et al. Does prophylaxis-delay in bipolar disorder influence outcome? Results from a long-term study of 147 patients. Acta Psychiatr. Scand. 107(4), 260-267 (2003).
14. Goldberg JF, Ernst CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J. Clin. Psychiatry 63(11), 985-991 (2002).
15. Cha B, Kim JH, Ha TH, Chang JS, Ha K. Polarity of the first episode and time to diagnosis of bipolar I disorder. Psychiatry Investig. 6(2), 96-101 (2009).
16. Gazalle FK, Andreazza AC, Ceresér KM, Hallal PC, Santin A, Kapczinski F. Clinical impact of late diagnose of bipolar disorder. J. Affect. Disord. 86(2-3), 313-316 (2005).
17. Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J. Clin. Psychiatry 61(10), 804-808; quiz 809 (2000).
18. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord. 5(6), 421-433 (2003).
19. Akiskal HS. Searching for behavioral indicators of bipolar II in patients presenting with major depressive episodes: the 'red sign', the 'rule of three' and other biographic signs of temperamental extravagance, activation and hypomania. J. Affect. Disord. 84(2-3), 279-290 (2005).
20. Angst J, Azorin JM, Bowden CL et al.; BRIDGE Study Group. Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE study. Arch. Gen. Psychiatry 68(8), 791-798 (2011).
21. Matza LS, Rajagopalan KS, Thompson CL, de Lissovoy G. Misdiagnosed patients with bipolar disorder: comorbidities, treatment patterns, and direct treatment costs. J. Clin. Psychiatry 66(11), 1432-1440 (2005).
22. Frances A, Jones KD. Bipolar disorder type II revisited. Bipolar Disord. 14(5), 474-477 (2012).
23. Zimmerman M. Broadening the concept of bipolar disorder: what should be done in the face of uncertainty? World Psychiatry 10(3), 188-189 (2011).
24. DelBello MP, Geller B. Review of studies of child and adolescent offspring of bipolar parents. Bipolar Disord. 3(6), 325-334 (2001).
25. Akiskal HS, Downs J, Jordan P, Watson S, Daugherty D, Pruitt DB. Affective disorders in referred children and younger siblings of manic-depressives. Mode of onset and prospective course. Arch. Gen. Psychiatry 42(10), 996-1003 (1985).
26. Hillegers MH, Reichart CG, Wals M, Verhulst FC, Ormel J, Nolen WA. Five-year prospective outcome of psychopathology in the adolescent offspring of bipolar parents. Bipolar Disord. 7(4), 344-350 (2005).
27. Baldessarini RJ, Tondo L, Vazquez GH et al. Age at onset versus family history and clinical outcomes in 1,665 international bipolar-I disorder patients. World Psychiatry 11(1), 40-46 (2012).
28. Duffy A, Alda M, Crawford L, Milin R, Grof P. The early manifestations of bipolar disorder: a longitudinal prospective study of the offspring of bipolar parents. Bipolar Disord. 9(8), 828-838 (2007).
29. Duffy A, Alda M, Hajek T, Sherry SB, Grof P. Early stages in the development of bipolar disorder. J. Affect. Disord. 121(1-2), 127-135 (2010).
30. Duffy A. The early course of bipolar disorder in youth at familial risk. J. Can. Acad. Child Adolesc. Psychiatry 18(3), 200-205 (2009).
31. Birmaher B, Axelson D, Monk K et al. Lifetime psychiatric disorders in schoolaged offspring of parents with bipolar disorder: the Pittsburgh Bipolar Offspring study. Arch. Gen. Psychiatry 66(3), 287-296 (2009).
32. Bella T, Goldstein T, Axelson D et al. Psychosocial functioning in offspring of parents with bipolar disorder. J. Affect. Disord. 133(1-2), 204-211 (2011).
33. Birmaher B, Axelson D, Goldstein B et al. Psychiatric disorders in preschool offspring of parents with bipolar disorder: the Pittsburgh Bipolar Offspring Study (BIOS). Am. J. Psychiatry 167(3), 321-330 (2010).
34. Lapalme M, Hodgins S, LaRoche C. Children of parents with bipolar disorder: a metaanalysis of risk for mental disorders. Can. J. Psychiatry. 42(6), 623-631 (1997).
35. Duffy A, Doucette S, Lewitzka U, Alda M, Hajek T, Grof P. Findings from bipolar offspring studies: methodology matters. Early Interv. Psychiatry 5(3), 181-191 (2011).
36. Alda M. The phenotypic spectra of bipolar disorder. Eur. Neuropsychopharmacol. 14(Suppl. 2), S94-S99 (2004).
37. Chang KD, Dienes K, Blasey C, Adleman N, Ketter T, Steiner H. Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms. J. Clin. Psychiatry 64(8), 936-942 (2003).
38. DelBello MP, Adler CM, Whitsel RM, Stanford KE, Strakowski SM. A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J. Clin. Psychiatry 68(5), 789-795 (2007).
39. Findling RL, Frazier TW, Youngstrom EA et al. Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder. J. Clin. Psychiatry 68(5), 781-788 (2007).
40. McNamara RK, Nandagopal JJ, Strakowski SM, DelBello MP. Preventative strategies for early-onset bipolar disorder: towards a clinical staging model. CNS Drugs 24(12), 983-996 (2010).
41. Miklowitz DJ, Chang KD, Taylor DO et al. Early psychosocial intervention for youth at risk for bipolar I or II disorder: a one-year treatment development trial. Bipolar Disord. 13(1), 67-75 (2011).
42. Fristad MA, Verducci JS, Walters K, Young ME. Impact of multifamily psychoeducational psychotherapy in treating children aged 8 to 12 years with mood disorders. Arch. Gen. Psychiatry 66(9), 1013-1021 (2009).
43. Hasler G, Drevets WC, Gould TD, Gottesman II, Manji HK. Toward constructing an endophenotype strategy for bipolar disorders. Biol. Psychiatry 60(2), 93-105 (2006).
44. Correll CU, Penzner JB, Lencz T et al. Early identification and high-risk strategies for bipolar disorder. Bipolar Disord. 9(4), 324-338 (2007).
45. Strakowski SM, Adler CM, Almeida J et al. The functional neuroanatomy of bipolar disorder: a consensus model. Bipolar Disord. 14(4), 313-325 (2012).
46. Hajek T, Carrey N, Alda M. Neuroanatomical abnormalities as risk factors for bipolar disorder. Bipolar Disord. 7(5), 393-403 (2005).
47. Hajek T, Gunde E, Slaney C et al. Amygdala and hippocampal volumes in relatives of patients with bipolar disorder: a high-risk study. Can. J. Psychiatry. 54(11), 726-733 (2009).
48. Hajek T, Gunde E, Slaney C et al. Striatal volumes in affected and unaffected relatives of bipolar patients - high-risk study. J. Psychiatr. Res. 43(7), 724-729 (2009).
49. Hajek T, Kopecek M, Höschl C. Reduced hippocampal volumes in healthy carriers of brain-derived neurotrophic factor Val66Met polymorphism: meta-analysis. World J. Biol. Psychiatry 13(3), 178-187 (2012).
50. Altshuler LL, Curran JG, Hauser P, Mintz J, Denicoff K, Post R. T2 hyperintensities in bipolar disorder: magnetic resonance imaging comparison and literature meta-analysis. Am. J. Psychiatry 152(8), 1139-1144 (1995).
51. Videbech P. MRI findings in patients with affective disorder: a meta-analysis. Acta Psychiatr. Scand. 96(3), 157-168 (1997).
52. Sprooten E, Sussmann JE, Clugston A et al. White matter integrity in individuals at high genetic risk of bipolar disorder. Biol. Psychiatry 70(4), 350-356 (2011).
53. Simonsen C, Sundet K, Vaskinn A et al. Neurocognitive profiles in bipolar I and bipolar II disorder: differences in pattern and magnitude of dysfunction. Bipolar Disord. 10(2), 245-255 (2008).
54. Thompson JM, Gallagher P, Hughes JH et al. Neurocognitive impairment in euthymic patients with bipolar affective disorder. Br. J. Psychiatry 186, 32-40 (2005).
55. Hellvin T, Sundet K, Simonsen C et al. Neurocognitive functioning in patients recently diagnosed with bipolar disorder. Bipolar Disord. 14(3), 227-238 (2012).
56. Savitz J, Solms M, Ramesar R. Neuropsychological dysfunction in bipolar affective disorder: a critical opinion. Bipolar Disord. 7(3), 216-235 (2005).
57. Savitz JB, Solms M, Ramesar RS. Neurocognitive function as an endophenotype for genetic studies of bipolar affective disorder. Neuromolecular Med. 7(4), 275-286 (2005).
58. Kulkarni S, Jain S, Janardhan Reddy YC, Kumar KJ, Kandavel T. Impairment of verbal learning and memory and executive function in unaffected siblings of probands with bipolar disorder. Bipolar Disord. 12(6), 647-656 (2010).
59. Balanzá-Martínez V, Rubio C, Selva- Vera G et al. Neurocognitive endophenotypes (endophenocognitypes) from studies of relatives of bipolar disorder subjects: a systematic review. Neurosci. Biobehav. Rev. 32(8), 1426-1438 (2008).
60. Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J. Affect. Disord. 113(1-2), 1-20 (2009).
61. Szöke A, Schürhoff F, Golmard JL et al. Familial resemblance for executive functions in families of schizophrenic and bipolar patients. Psychiatry Res. 144(2-3), 131-138 (2006).
62. Whalley LJ, Perini T, Shering A, Bennie J. Melatonin response to bright light in recovered, drug-free, bipolar patients. Psychiatry Res. 38(1), 13-19 (1991).
63. Hallam KT, Olver JS, Chambers V, Begg DP, McGrath C, Norman TR. The heritability of melatonin secretion and sensitivity to bright nocturnal light in twins. Psychoneuroendocrinology 31(7), 867-875 (2006).
64. Nurnberger JI Jr, Adkins S, Lahiri DK et al. Melatonin suppression by light in euthymic bipolar and unipolar patients. Arch. Gen. Psychiatry 57(6), 572-579 (2000).
65. Berger M, Riemann D, Höchli D, Spiegel R. The cholinergic rapid eye movement sleep induction test with RS-86. State or trait marker of depression? Arch. Gen. Psychiatry 46(5), 421-428 (1989).
66. Anand A, Verhoeff P, Seneca N et al. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am. J. Psychiatry 157(7), 1108-1114 (2000).
67. Barrett TB, Hauger RL, Kennedy JL et al. Evidence that a single nucleotide polymorphism in the promoter of the G protein receptor kinase 3 gene is associated with bipolar disorder. Mol. Psychiatry 8(5), 546-557 (2003).
68. Peet M, Peters S. Drug-induced mania. Drug Saf. 12(2), 146-153 (1995).
69. Kathmann N, Hochrein A, Uwer R, Bondy B. Deficits in gain of smooth pursuit eye movements in schizophrenia and affective disorder patients and their unaffected relatives. Am. J. Psychiatry 160(4), 696-702 (2003).
70. Rosenberg DR, Sweeney JA, Squires- Wheeler E, Keshavan MS, Cornblatt BA, Erlenmeyer-Kimling L. Eye-tracking dysfunction in offspring from the New York High-Risk Project: diagnostic specificity and the role of attention. Psychiatry Res. 66(2-3), 121-130 (1997).
71. Thaker GK. Neurophysiological endophenotypes across bipolar and schizophrenia psychosis. Schizophr. Bull. 34(4), 760-773 (2008).
72. Franks RD, Adler LE, Waldo MC, Alpert J, Freedman R. Neurophysiological studies of sensory gating in mania: comparison with schizophrenia. Biol. Psychiatry 18(9), 989-1005 (1983).
73. Sánchez-Morla EM, García-Jiménez MA, Barabash A et al. P50 sensory gating deficit is a common marker of vulnerability to bipolar disorder and schizophrenia. Acta Psychiatr. Scand. 117(4), 313-318 (2008).
74. Hall MH, Schulze K, Sham P et al. Further evidence for shared genetic effects between psychotic bipolar disorder and P50 suppression: a combined twin and family study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B(5), 619-627 (2008).
75. Hall MH, Rijsdijk F, Kalidindi S et al. Genetic overlap between bipolar illness and event-related potentials. Psychol. Med. 37(5), 667-678 (2007).
76. O'Donnell BF, Vohs JL, Hetrick WP, Carroll CA, Shekhar A. Auditory event-related potential abnormalities in bipolar disorder and schizophrenia. Int. J. Psychophysiol. 53(1), 45-55 (2004).
77. Schulze KK, Hall MH, McDonald C et al. Auditory P300 in patients with bipolar disorder and their unaffected relatives. Bipolar Disord. 10(3), 377-386 (2008).
78. Martínez-Arán A, Vieta E, Colom F et al. Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. Bipolar Disord. 6(3), 224-232 (2004).
79. Rich BA, Vinton D, Grillon C, Bhangoo RK, Leibenluft E. An investigation of prepulse inhibition in pediatric bipolar disorder. Bipolar Disord. 7(2), 198-203 (2005).
80. Chiaroni P, Hantouche EG, Gouvernet J, Azorin JM, Akiskal HS. The cyclothymic temperament in healthy controls and familially at risk individuals for mood disorder: endophenotype for genetic studies? J. Affect. Disord. 85(1-2), 135-145 (2005).
81. Kochman FJ, Hantouche EG, Ferrari P, Lancrenon S, Bayart D, Akiskal HS. Cyclothymic temperament as a prospective predictor of bipolarity and suicidality in children and adolescents with major depressive disorder. J. Affect. Disord. 85(1-2), 181-189 (2005).
82. Almeida KM, Nery FG, Moreno RA, Gorenstein C, Lafer B. Personality traits in bipolar disorder type I: a sib-pair analysis. Bipolar Disord. 13(7-8), 662-669 (2011).
83. Post RM. The impact of bipolar depression. J. Clin. Psychiatry 66(Suppl. 5), 5-10 (2005).
84. Scott EM, Hermens DF, Naismith SL et al. Distinguishing young people with emerging bipolar disorders from those with unipolar depression. J. Affect. Disord. 144(3), 208-215 (2013).
85. Parker G, Roy K, Wilhelm K, Mitchell P, Hadzi-Pavlovic D. The nature of bipolar depression: implications for the definition of melancholia. J. Affect. Disord. 59(3), 217-224 (2000).
86. Mitchell PB, Wilhelm K, Parker G, Austin MP, Rutgers P, Malhi GS. The clinical features of bipolar depression: a comparison with matched major depressive disorder patients. J. Clin. Psychiatry 62(3), 212-216; quiz 217 (2001).
87. Perlis RH, Brown E, Baker RW, Nierenberg AA. Clinical features of bipolar depression versus major depressive disorder in large multicenter trials. Am. J. Psychiatry 163(2), 225-231 (2006).
88. Benazzi F. Psychomotor changes in melancholic and atypical depression: unipolar and bipolar-II subtypes. Psychiatry Res. 112(3), 211-220 (2002).
89. Mitchell PB, Goodwin GM, Johnson GF, Hirschfeld RM. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord. 10(1 Pt 2), 144-152 (2008).
90. Hirschfeld RM, Williams JB, Spitzer RL et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am. J. Psychiatry 157(11), 1873-1875 (2000).
91. Hirschfeld RM, Calabrese JR, Weissman MM et al. Screening for bipolar disorder in the community. J. Clin. Psychiatry 64(1), 53-59 (2003).
92. Hirschfeld RM. The mood disorder questionnaire: its impact on the field [corrected]. Depress. Anxiety 27(7), 627-630 (2010).
93. Zimmerman M, Galione JN, Ruggero CJ et al. Performance of the mood disorders questionnaire in a psychiatric outpatient setting. Bipolar Disord. 11(7), 759-765 (2009).
94. Conus P, Ward J, Hallam KT et al. The proximal prodrome to first episode mania - a new target for early intervention. Bipolar Disord. 10(5), 555-565 (2008).
95. Conus P, Ward J, Lucas N et al. Characterisation of the prodrome to a first episode of psychotic mania: results of a retrospective study. J. Affect. Disord. 124(3), 341-345 (2010).
96. Bechdolf A, Nelson B, Cotton SM et al. A preliminary evaluation of the validity of at-risk criteria for bipolar disorders in help-seeking adolescents and young adults. J. Affect. Disord. 127(1-3), 316-320 (2010).
97. Skjelstad DV, Malt UF, Holte A. Symptoms and signs of the initial prodrome of bipolar disorder: a systematic review. J. Affect. Disord. 126(1-2), 1-13 (2010).
98. Brietzke E, Mansur RB, Soczynska JK, Kapczinski F, Bressan RA, McIntyre RS. Towards a multifactorial approach for prediction of bipolar disorder in at risk populations. J. Affect. Disord. 140(1), 82-91 (2012).
99. Leopold K, Ritter P, Correll CU et al. Risk constellations prior to the development of bipolar disorders: rationale of a new risk assessment tool. J. Affect. Disord. 136(3), 1000-1010 (2012).
100. Hauser M, Pfennig A, Ozgürdal S, Heinz A, Bauer M, Juckel G. Early recognition of bipolar disorder. Eur. Psychiatry 22(2), 92-98 (2007).
101. Bechdolf A, Ratheesh A, Wood SJ et al. Rationale and first results of developing at-risk (prodromal) criteria for bipolar disorder. Curr. Pharm. Des. 18(4), 358-375 (2012).
102. Berk M, Conus P, Lucas N et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord. 9(7), 671-678 (2007).
103. Macneil CA, Hallam K, Conus P, Henry L, Kader L, Berk M. Are we missing opportunities for early intervention in bipolar disorder? Expert Rev. Neurother. 12(1), 5-7 (2012).
104. McIntyre RS, Cha DS, Jerrell JM et al. Employing 'big data' for the prediction of bipolar disorder. Bipolar Disord. (2013) (In Press).
105. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust. NZ J. Psychiatry 40(8), 616-622 (2006).